<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82205">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780948</url>
  </required_header>
  <id_info>
    <org_study_id>A7478</org_study_id>
    <nct_id>NCT01780948</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic of Everolimus and Atorvastatin Co-administration</brief_title>
  <official_title>Drug Interaction and Pharmacokinetic Assessment of Everolimus When Coadministered With Atorvastatin in Renal Transplantation Recipient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ratchadapiseksompotch Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <authority>Thailand: Ethical Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis : In renal transplantation recipient who received immunosuppressive drug
      &quot;certican&quot; and have hypercholesterolemia will get lipid lower drug-HMG Co-A reductase
      inhibitors. Because atorvastatin and everolimus have metabolism via Cytochrome P450
      subfamily 3A4 both, so investigator made the hypothesis that when patients received
      everolimus with atorvastatin will change area under the time concentration curve of
      everolimus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Population : Thai postrenal transplantation recipient who received everolimus and have
      hypercholesterolemia in posttransplantation clinic at Faculty of Medicine, Chulalongkorn
      University.

      Study Design : Experimental study, Two-sample crossover study Sample size calculation :N =
      18 Primary outcome : 12-hour area under the time concentration curve of everolimus Secondary
      outcome : renal function (serum creatinine, creatinine clearance)

      Method :

        1. Patients will random to everolimus or everolimus with atorvastatin 20 mg arm for 1
           month.

        2. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8,
           12 hour

        3. After first blood sample, patients will received everolimus only for 1 month (wash out
           period)

        4. Patients will switch to another arm eg.patient who had received everolimus will switch
           to everolimus with atorvastatin 20 mg for 1 month

        5. Take blood sample for everolimus concentration at time 0,0.5, 1, 1.5, 2, 2.5, 4, 6, 8,
           12 hour

        6. Everolimus level will analyse for 12-hour AUC of everolimus.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>12-hour area under the time concentration curve of everolimus</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>compare when taking only everolimus to coadministered with atorvastatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Renal function : serum creatinine, 24 hour creatinine clearance 24 hour urine protein, Urinalysis Sample take at month 0,1,2,3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function test</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Total protein, Albumin, total bilirubin, direct bilirubin, AST, ALT, Alkaline phosphatase at month 0,1,2,3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Total cholesterol, Triglyceride, HDL, LDL at month 0,1,2,3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhabdomyolysis</measure>
    <time_frame>3 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse drug reaction from atorvastatin by measured CPK at month 0,1,2,3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of 12-hour AUC and point of everolimus level</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To correlate between 12-hour AUC and point of everolimus level</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Difference of 12-hour AUC</condition>
  <arm_group>
    <arm_group_label>everolimus</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Everolimus administration with adjusted dose to target C trough (C0) level between 3-12 ng/mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>everolimus with atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Co-administration of everolimus and atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
Atorvastatin 20 mg/day (fixed dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg</intervention_name>
    <description>Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg</description>
    <arm_group_label>everolimus</arm_group_label>
    <other_name>Lipitor 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.</description>
    <arm_group_label>everolimus with atorvastatin 20 mg</arm_group_label>
    <other_name>Everolimus alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post renal transplantation recipient who received immunosuppressive drug Everolimus
             and has hypercholesterolemia

          -  Co everolimus level within 3-12 ng/mL

          -  Informed consent

          -  Patient can follow research methodology

        Exclusion Criteria:

          -  Patient don't want to participate in the study

          -  Post renal transplantation recipient who have normal lipid profile
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anocha Wanitchanont, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Kovarik JM, Hartmann S, Hubert M, Berthier S, Schneider W, Rosenkranz B, Rordorf C. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus. J Clin Pharmacol. 2002 Feb;42(2):222-8.</citation>
    <PMID>11831546</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 7, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>ANOCHA WANITCHANONT</investigator_full_name>
    <investigator_title>Department of Medicine, Faculty of Medicine, Chulalongkorn University</investigator_title>
  </responsible_party>
  <keyword>Drug Interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Atorvastatin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
